Instruction for use: Plidol 100

Active substance Acetylsalicylic acid

ATX code B01AC06 Acetylsalicylic acid

Pharmacological groups

Antiaggregants

NSAIDs - Salicylic acid derivatives in combinations

Nosological classification (ICD-10)

I20.0 Unstable angina

Unstable angina, heberden disease

I21 Acute myocardial infarction

Myocardial infarction in the acute phase, Acute Myocardial Infarction, Myocardial infarction with pathologic Q wave and without, Myocardial infarction complicated by cardiogenic shock, Infarction left ventricular, Transmural myocardial infarction, Myocardial infarction netransmuralny (subendocardial), Netransmuralny myocardial infarction, Subendocardial myocardial infarction, The acute phase of myocardial infarction, Acute myocardial infarction, Sub-acute phase of myocardial infarction, Subacute phase of myocardial infarction, Thrombosis of the coronary arteries (the arteries), Threatened myocardial infarction, Myocardial infarction without Q wave

I25 Chronic ischemic heart disease

Coronary heart disease on the background of hypercholesterolemia, Coronary heart disease is a chronic, Coronary heart disease, Stable coronary artery disease, Percutaneous transluminal angioplasty, Myocardial ischemia, arteriosclerosis, Recurrent myocardial ischemia

I63 Cerebral infarction

Stroke ischemic, Ischemic disease of the brain, Ischemic stroke, Ischemic stroke and its consequences, Ischemic cerebral stroke, Ischemic impairment of cerebral circulation, Ischemic damage of the brain, Ischemic brain damage, Ischemic state, Ischemia of the brain, Acute hypoxia of the brain, Acute cerebral ischemia, Acute ischemic impairment of cerebral circulation, Acute cerebral infarction, Acute ischemic stroke, Acute period of ischemic stroke, Focal cerebral ischemia, Postponed ischemic stroke, Repeated stroke, Morgagni-Adams-Stokes Syndrome, Chronic cerebral ischemia, Cerebrovascular stroke, Embolic Stroke, Ischemic brain damage

I74 Embolism and arterial thrombosis

Thrombosis of effort (tension), Arterial thrombosis, Arteriothrombosis, Subacute and chronic arterial thrombosis, Subacute thrombosis of peripheral arteries, Postoperative thrombosis, Vascular thrombosis, Vascular embolism, Thrombosis of aortocoronary shunt, Arterial thrombosis, Thrombosis of arteries, Coronary artery thrombosis, Coronary thrombosis, Thrombosis of blood vessels, Thrombosis with ischemic stroke, Thrombosis with general surgical operations, Thrombosis in Oncology Operations, Vascular thrombosis, Thrombus formation in the postoperative period, Thrombotic complications. Thromboembolic diseases, Thromboembolic complications, Thromboembolic syndrome, Thromboembolic complication, Thromboembolic complication in the postoperative period, Thromboembolism of arteries, Partial vascular thrombosis, Embolism, Embolism of arteries

R07.2 Pain in the heart

neuroses of the heart, Myocardial ischemic pain, Pain syndrome in myocardial infarction, cardialgia, cardioneurosis, Cardiac syndrome, Pain in cardiac patients, Cardialgia on background dyshormonal myocardial dystrophy, Functional cardialgia, Psevdostenokardiya, pericardial pain

Composition and form of release

1 tablet contains 100 mg of acetylsalicylic acid; in the blister 10 pcs., in the box 2 blisters.

pharmachologic effect

Pharmacological action - antiaggregational.

It inhibits cyclooxygenase and reduces the synthesis of thromboxane A2, which has a pro-aggregative effect.

Pharmacokinetics

After taking 1 table. reliable concentrations are detected in the blood after 30 minutes, Cmax is reached within 1-2 hours. It is quickly distributed through tissues and liquids, easily passes through the placental barrier, weakly penetrates into the cerebrospinal fluid. T1 / 2 - 2-3 hours. It is excreted by the kidneys, lactating mammary glands.

Indications

Prevention and treatment of conditions accompanied by increased aggregation of platelets: acute myocardial infarction, cerebrovascular stroke; treatment of unstable angina and transient attacks of IHD (ischemic heart disease) (additional therapy); prevention of thrombosis of aortocoronary shunt.

Contraindications

Hypersensitivity (including to other salicylates), peptic ulcer of the stomach and duodenum (stage of exacerbation), hemorrhagic diathesis.

Side effects

Nausea, anorexia, pain in the epigastric region, erosive and ulcerative lesions and latent bleeding GIT (gastrointestinal tract), impaired liver and kidney function, thrombocytopenia, allergic reactions.

Interaction

Strengthens the effect of anticoagulants and oral hypoglycemic agents, NSAIDs (nonsteroidal anti-inflammatory drugs), side effects of methotrexate, reduces the effectiveness of antidotal drugs.

Dosing and Administration

Inside, the course and dose are set individually; in a usual dose - on 100 mg daily.

Storage Conditions

At a temperature of 15-25 ° C.

Keep out of the reach of children.

Shelf life

2 years.

Do not use after the expiry date printed on the package.